A tremendous vote of confidence in GBI's future to have such...

A tremendous vote of confidence in GBI's future to have such world experts join them in providing advice. Prof Jack Cuzick is recognised as one of the top scientists of the past decade and it's extraordinary that he and the other eminent Board members have come together. (You certainly wouldn't want to be associated with a company, people or products that have not been subject to careful due diligence and that have no future.)

Cuzick was responsible for the Predictors 3 study of 6,000 Thin Prep samples to determine the efficacy of different types of screening for HPV. He is likely to publish the results of the study in the next few months and he has stated that he was impressed by the performance of GBI's test against market leaders.

GBI's share price seems very low, perhaps because they've said they were on the cusp of a major commercial event (buyout, partnership/marketing deal) almost every six months. The most recent Annual Report published a month ago said that were looking for a IVD partnership by end of this year and ideally prior to the AGM in late November. Even if they are still a couple of months late, it seems that a deal is very close. Hopefully we will get news of a useful capital injection, issue of shares at a much higher price and a global sales and marketing agreement to boost sales and accelerate development of other products.

The fact that GBI now has an Advisory Board suggests that they see excellent medium and long term prospects and are not likely to sell out before developing and bringing to value the prospects ahead of them. Good stuff!